Valion Bio, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Valion Bio, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $429.00K, a 2760.00% increase year-over-year.
- Valion Bio, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.91M.
- Valion Bio, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.70M.
- Valion Bio, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $15.00K, a 99.64% decline year-over-year.
- Valion Bio, Inc. stock issued during period, value, new issues for fiscal 2025 was $4.04M.
- Valion Bio, Inc. stock issued during period, value, new issues for fiscal 2023 was $7.56M.
- Valion Bio, Inc. stock issued during period, value, new issues for fiscal 2021 was $14.56M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $4.04M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $429.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.91M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $1.70M 10-Q · filed 2025-11-14 | |
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $7.56M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $4.15M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $3.41M 10-Q · filed 2024-11-14 | |
| 2021-12-31 | $14.56M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |